Phase I Study of Daily RAD001 in Combination With Mitomycin C in Patients With Advanced Gastric Cancer or Cancer of the Esophagogastric Junction

Phase 1

Completed

• Conditions: Advanced Gastric Cancer; Advanced Cancer of the Esophagogastric Junction
• Interventions: Drug: RAD001 and MitomycinC

• Registration Number: NCT01042782
• Lead Sponsor: Krankenhaus Nordwest

Brief Summary

Patients with advanced gastric cancer are treated with a combination of RAD001 (everolimus) and Mitomycin C.

Detailed Description

The purpose of this monocenter, single-arm, phase I trial is to determine the maximum-tolerated-dose, dose-limiting toxicity (DLT) and preliminary efficacy and safety of RAD001 in combination with Mitomycin C in patients with advanced gastric cancer.

Study Timeline

• Study Start: 2008-01
• Study First Submitted: 2010-01-05
• Study First Submitted QC: 2010-01-05
• Study First Posted: 2010-01-06
• Status Verified: 2012-08
• Primary Completion: 2012-08
• Study Completion: 2012-08
• Last Update Submitted: 2012-08-02
• Last Update Posted: 2012-08-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• 1 prior platin containing chemotherapy in the palliativ setting or progressive disease under adjuvant or neoadjuvant therapy within 6 months of treatment start date.
• Histological evidence of advanced or metastatic gastric cancer or cancer of the esophageal junction.
• At baseline CT or MRI scan must demonstrate measurable disease by RECIST criteria, i.e., the presence of at least one measurable lesion. Measurable disease lesions must be accurately measured in at least one dimension with longest diameter > 20 mm using conventional techniques or > 10 mm with spiral CT scan (with minimum lesion size no less than double the slice thickness).
• At least one measurable lesion outside of the field of any prior radiation therapy (according to RECIST criteria). Prior radiotherapy to a single index lesion is not allowed.
• Adult male or female patients (≥18 years of age).
• Patients must have disease not amenable to surgery, radiation, or combined modality therapy with curative intent.
• ECOG 0 or 1
• Life expectance >4 months
• Adequate bone marrow function, renal function, liver function
• Women using an acceptable form of contraception prior to receiving RAD001 or women who meet the protocol definition of post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m or 6 weeks post surgical bilateral oophorectomy with or without hysterectomy.
• Fully recovered from any previous surgery, prior chemotherapy or radiation therapy (at least 4 weeks since major surgery or prior myelosuppressive chemotherapy). With the exception of alopecia, patients must have resolution of all acute toxic effects of any prior surgery, radiotherapy, or chemotherapy to NCI CTC (Version 2.0) grade <=1. Patients with rapidly progressive tumors (upon the decision of the investigator) can be treated <4 weeks since last chemotherapy, if they fully recovered from all side effects.
• Signed informed consent

Exclusion Criteria

• Anticancer therapy within 3 weeks of enrollment including chemotherapy, hormonal therapy, immunotherapy, or radiotherapy. Patients with rapidly progressive tumors (upon the decision of the investigator) can be treated <4 weeks since last chemotherapy, if they fully recovered from all side effects.
• Prior therapy with RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus).
• Patients treated with Mitomycin C
• No neurotoxicity >= grade 2 CTC
• No gastric or intestinal obstruction
• Patients taking drugs known to inhibit or induce isoenzyme CYP3A
• Patients with any concurrent major medical condition liable to compromise the patient's participation in the study (e.g known HIV infection, uncontrolled diabetes, serious cardiac dysrhythmia or condition, New York Heart Association classification of III or IV, congestive cardiac failure, myocardial infarction within 6 months, unstable angina, chronic or acute renal or liver disease, uncontrolled serious infections including abscess or fistulae, etc.)
• Patients with a history of another malignancy prior to study entry, except curatively treated non-melanotic skin cancer or carcinoma in-situ cervical cancer unless in complete remission or no evidence of disease and off all therapy for that disease for a minimum of 5 years
• No symptomatic brain metastasis.
• Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
• Female patients who are pregnant or breast feeding
• History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures
• History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
RAD-MitC	RAD001 and MitomycinC	RAD001 orally daily 5mg or 7.5mg or 10mg Mitomycin C 5mg/m2 every 3 weeks

Primary Outcome Measures

Name	Time	Method
maximum tolerated-dose (MTD) of RAD001 in combination with Mitomycin C	every week

Secondary Outcome Measures

Name	Time	Method
overall survival (OS)	every three months
preliminary efficacy of RAD001 in refractory gastric cancer. Efficacy is defined as complete response or partial response at 12 weeks based on RECIST-criteria	every 6 weeks
progression-free survival (PFS)	every 6 weeks
safety and tolerability of the combination of RAD001 and Mitomycin C as assessed by frequency, severity, and duration of treatment-related adverse effects	every week

Trial Locations

Locations (1)

Krankenhaus Nordwest; 🇩🇪 Frankfurt, Germany